Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nantes, France, 44093
- Nantes university hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient above 18 years old
- Suffering from typical symptoms of reflux (heartburn and/or acid regurgitation and/or epigastric burns with ascending radiations)
- Symptoms occurring at least 3 times a week without treatment
- Symptoms disappearing under full doses PPI treatment
- Requiring a continuous treatment for more than 3 months to get rid of symptoms (or nearly)
- Total consent signed from patient
Exclusion Criteria:
Contraindications to the radiofrequency technique:
- Columnar lined oesophagus ³ 3 cm height
- Barret's mucosa presenting dysplasia
- History of treated columnar lined oesophagus
- Hiatus hernia with a size over 3 cm
- History of Stage C or D esophagitis in the Los Angeles classification (18), or in progress
- History of oesophageal stenosis
- History of gastric or oesophageal surgery
- Presence of oesophageal and/or cardial varicose veins
- Presence of a cardiac pacemaker or implanted defibrillator (when confirmed by the manufacturer that use of RF energy will not interfere, it's ok to do patients!)
- Impossibility to interrupt a anticoagulant treatment or serious disorders of haemostasis
General contraindications:
- Contraindication to general anaesthesia
- Existence of an associated serious disease making fear that the patient will live less than a year
- Incapacity to understand and sign a sensible consent of participation to the study
- Chronic alcoholism defined by a daily consumption of alcohol over 60 g
- Morbid obesity defined by a rate of body mass higher that 35
- Patients suffering from atypical GERD symptoms (especially extra-digestive) will not be included in the study if these symptoms are not associated with typical reflux symptoms (heartburn or regurgitation)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The main endpoint will be the possibility or not to stop the PPI treatment (or to reduce the dose by at least 50%), 6 months after administering (or not) just one radiofrequency session.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
The evaluation of tolerance,
|
|
the description of potential complications entailed by the technique and the measure of GERD recurrence rate on patients over a one-year period.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BRD/03/6-F
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.